In this section
@article{Bandyopadhyay:2024:10.1016/S1473-3099(23)00505-4,
author = {Bandyopadhyay, AS and Lopez, Cavestany R and Blake, IM and Macklin, G and Cooper, L and Grassly, N and Nery, ALMDS and Mach, O},
doi = {10.1016/S1473-3099(23)00505-4},
journal = {Lancet Infect Dis},
pages = {e328--e342},
title = {Use of inactivated poliovirus vaccine for poliovirus outbreak response.},
url = {http://dx.doi.org/10.1016/S1473-3099(23)00505-4},
volume = {24},
year = {2024}
}
TY - JOUR
AB - With continued wild poliovirus transmission in Afghanistan and Pakistan and circulating vaccine-derived poliovirus in certain countries, there exists an ongoing risk of importation of polioviruses into other countries, including those that have been polio-free for decades. Diversifying the poliovirus outbreak response toolkit is essential to account for different public health and epidemiological contexts. In this Personal View, we discuss data on intestinal and pharyngeal mucosal immunity induced by inactivated poliovirus vaccine (IPV), previous programmatic experience of poliovirus outbreak response with IPV, and outbreak response guidelines in countries that exclusively use IPV. With recent reports of poliovirus detection in polio-free countries such as the USA and the UK, it is important to assess the interplay of virus transmission dynamics, vaccine impact on preventing paralysis and virus spread, and regulatory complexities of using oral poliovirus vaccine (OPV) and IPV options for outbreak response. As the global eradication programme navigates through cessation of routine OPV use with replacement by IPV and stockpiling of novel OPVs, clarity on the impact of IPV use will be important for informed decision making by global, regional, and national policy makers.
AU - Bandyopadhyay,AS
AU - Lopez,Cavestany R
AU - Blake,IM
AU - Macklin,G
AU - Cooper,L
AU - Grassly,N
AU - Nery,ALMDS
AU - Mach,O
DO - 10.1016/S1473-3099(23)00505-4
EP - 342
PY - 2024///
SP - 328
TI - Use of inactivated poliovirus vaccine for poliovirus outbreak response.
T2 - Lancet Infect Dis
UR - http://dx.doi.org/10.1016/S1473-3099(23)00505-4
UR - https://www.ncbi.nlm.nih.gov/pubmed/38012892
VL - 24
ER -
For any enquiries related to the MRC Centre please contact:
Scientific Manager
Susannah Fisher
mrc.gida@imperial.ac.uk
External Relationships and Communications Manager
Dr Sabine van Elsland
s.van-elsland@imperial.ac.uk